Abstract: In a stainless-steel drum container (1) for the transport, storage and keeping-ready of liquids, in particular of liquid chemicals, having a cylindrical container body (2), which has a lid (3), a base (4) and a container opening (6), a gas supply opening (8) and a liquid removal opening (9) are arranged on the container body (2) at a distance from the container opening (6) and at a distance from one another. The gas supply opening (8) and the liquid removal opening (9) are each arranged in the lid (3). The gas supply opening (8) has a filling valve (10) and the liquid removal opening (9) has a removal valve (11). The filling valve (10) and the removal valve (11) are essentially of the same design. The filling valve (10) or the removal valve (11) has a coupling device (13, 14), which opens the filling valve (10) or the removal valve (11) when the filling valve (10) or the removal valve (11) respectively is connected to an associated connection line.

Abstract: The present invention relates to benzonaphthyridinamines of the formula (I) as autotaxin inhibitors and to the use thereof in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in which the inhibition, regulation and/or modulation of phosphodiesterase or lysophospholipase autotaxin plays a role, in particular of various types of cancer and autoimmune and inflammatory diseases.

Abstract: The present invention relates to a liquid-crystalline medium having high twist, to the use thereof for electro-optical purposes, and to displays containing this medium.

Abstract: The invention relates to novel polymers containing 8,9-dihydrobenzo[def]carbazole units, methods and materials for their preparation, their use as semiconductors in organic electronic (OE) devices, and to OE devices comprising these polymers.

Abstract: The invention relates to a process for the preparation of tris(perfluoroalkyl)phosphine oxides by reaction of tris(perfluoroalkyl)difluorophosphorane with alkaline-earth metal oxides, alkaline-earth metal carbonates, zinc oxide, copper(I) oxide, copper(II) oxide, silver oxide, mercury(II) oxide, cadmium oxide or cadmium carbonate

Abstract: The present invention relates to polymerisable compounds, to processes and intermediates for the preparation thereof, to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays having a polymer-stabilised blue phase, and in LC media for LC displays of the PS or PSA type (“polymer sustained” or “polymer sustained alignment”), and to LC media and LC displays comprising these compounds.

Abstract: The invention relates to liquid-crystalline mixtures comprising at least one compound of the formula I, in which X, L1, L2, L3, L4 and alkenyl have the meanings indicated in claim 1, in order to increase the pretilt at the polyimide surface, and to liquid-crystalline media comprising one or more compounds of the formula I in electro-optical liquid-crystal displays and in LC lenses.

Abstract: The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, in which R1, R1*, ring A have the meanings indicated in Claim 1, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS or IPS effect.

Abstract: The present invention relates to the use of phosphinic acids and/or phosphonic acids and salts thereof for wetting fluorine compounds, in particular fluoropolymers, to the use in coating solutions comprising fluorine compounds, and to polymerisation processes in which fluorine compounds are used and/or formed.

Abstract: The present invention relates to compounds of formula (I) wherein X, Y, Z, R1, R2, R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabetes, metabolic syndrome, obesity, cancer, inflammation.

Abstract: The present invention relates to a process for the treatment of electrodes in organic electronic (OE) devices, in particular organic field effect transistors (OFETs), to devices prepared by such a process, and to materials and formulations used in such a process.

Abstract: The instant invention relates electro-optical switching elements and displays comprising them. In particular, it relates to electro-optical switching elements comprising cholesteric liquid crystal layers, in particular, with both-handed twist senses, which selectively reflect visible light and/or light emitting moieties which are embedded in the cholesteric liquid crystal layers or other layers and an light controlling element that controls the amount of transmitted and/or reflected light. The displays give bright images under either bright or dark conditions with small power consumption. They are particularly suitable for e-paper applications and/or digital signage applications.

Abstract: Novel heterocyclic indazole derivatives of the formula (I), in which L, Q, R, X, Y, R3, R4 and R5 have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.

Abstract: Compounds of the formula (I), in which R1, R2, R3, D, G, Q and W have the meanings indicated in claim (1), can and be employed for the treatment of tumours.

Abstract: The invention relates to a liquid-crystalline medium comprising one or more compounds of the formula (I), in which R0 has the meanings indicated in Claim 1, and to the use thereof in electro-optical liquid-crystal displays.

Abstract: Novel hetarylaminonaphthyridine derivatives of formula (I) wherein X, R1, R2, R3, R4, W1, W2, W3, W5 and W6 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.

Abstract: The present invention relates to compounds of formula (I) wherein X, Y, Z, R1, R2, R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabetes, metabolic syndrome, obesity, cancer, inflammation.

Abstract: The invention relates to the use of imidazole derivatives of the formula (1): in which A, R?1, R?2 and R?3 are as defined in the description, as AMPK activators. The invention also relates to processes for the preparation of the said compounds, to their uses for the preparation of medicaments for the treatment of insulin resistance, diabetes and related pathologies, and also obesity, and to the pharmaceutical compositions comprising them. Certain compounds of the formula (1) are novel and, in this respect, also form part of the invention.

Abstract: Compounds selected from the group according to Claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.

Abstract: The invention relates to a method for quickly and effectively isolating and purifying five, namely the group 1, 2, 3, 10 and 13 allergens from grass pollen. The purification of said grass pollen is based on the inventive combination of hydrophobic interaction chromatography, gel filtration and cation exchange chromatography. The proteins obtained by the inventive method facilitate an improved diagnosis of pollen allergies and are used in pharmaceutical preparations for the therapy of pollenogenic diseases.